Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 04, 2021 07:30 ET | Source: Otonomy, Inc.

Otonomy to Report First Quarter 2021 Financial Results and Provide Corporate Update

SAN DIEGO, May 04, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will...
May 01, 2019 07:30 ET | Source: Otonomy, Inc.

Otonomy to Participate in SunTrust Robinson Humphrey Life Sciences Summit

SAN DIEGO, May 01, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced...
May 02, 2018 07:30 ET | Source: Otonomy, Inc.

Otonomy to Report First Quarter 2018 Financial Results and Provide Corporate Update

SAN DIEGO, May 02, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced it will...
September 13, 2017 07:30 ET | Source: Otonomy, Inc.

Otonomy Provides Business and Financial Update

Actions taken to reduce costs following suspension of OTIVIDEX™ developmentNon-commercial workforce reduced by one-thirdCurrent cash balance expected to fund company into 2020Review underway to...
August 30, 2017 07:00 ET | Source: Otonomy, Inc.

Otonomy Reports Results for AVERTS-1 Phase 3 Trial for OTIVIDEX™ in Patients with Ménière's Disease

Missed primary endpoint (p value = 0.62) and all key vertigo secondary endpointsCompany to immediately suspend all development activities for OTIVIDEXCompany is also undertaking a review of its...
August 03, 2017 16:12 ET | Source: Otonomy, Inc.

Otonomy Reports Second Quarter 2017 Financial Results and Provides Corporate Update

SAN DIEGO, Aug. 03, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
July 27, 2017 07:30 ET | Source: Otonomy, Inc.

Otonomy to Report Second Quarter 2017 Financial Results and Provide Corporate Update

SAN DIEGO, July 27, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
May 10, 2017 16:05 ET | Source: Otonomy, Inc.

Otonomy to Present at the Bank of America Merrill Lynch Health Care Conference

SAN DIEGO, May 10, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
October 04, 2016 07:30 ET | Source: Otonomy, Inc.

Otonomy Successfully Completes Phase 2 Clinical Trial of OTIPRIO® in Pediatric Patients with Acute Otitis Media with Tympanostomy Tubes

SAN DIEGO, Oct. 04, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
August 01, 2016 07:30 ET | Source: Otonomy, Inc.

Otonomy Successfully Completes One-Year, Multiple-Dose Clinical Safety Trial for OTO-104 in Ménière’s Disease Patients

SAN DIEGO, Aug. 01, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...

Next Page keyboard_arrow_right